ReviewFrontiers in immunology2025
Targeting the bacterial stringent response to combat human pathogens.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Rel mutations that increase basal (p)ppGpp promote conjugal transfer of staphylococcal resistance plasmids.Microbiology (Reading, England) · 2026Article
- Nanobody-mediated control of long RSH Rel and RelA catalysis by restriction of their conformational landscape.Nature communications · 2026Article
- Prokaryotic homeostasis - a solution to thrive and survive.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the era of increasing bacterial antibiotic resistance, finding new ways of combating pathogens is especially important. An attractive possibility is targeting bacterial survival strategies that microorganisms employ either to evade the host immune-responses or to adapt to the hostile environment encountered once inside the host. An example of the latter is the stringent response, mediated by guanosine penta- and tetra-phosphate, collectively referred to as (p)ppGpp. These molecules (alarmones) are responsible for switching bacterial gene expression and metabolism to allow survival under various stresses, such as nutritional deprivation and oxidative stress. (p)ppGpp turnover is mediated by various enzymes belonging to the RSH (RelA-SpoT homolog) family, some of which are capable of both, (p)ppGpp synthesis and hydrolysis, while others can perform only one of these functions. In this minireview, we discuss strategies that aim to disrupt or modulate the stringent response either by inhibiting these enzymes or on the contrary - enhancing their activities, as that goal can be achieved by several ways, i.e. blocking (p)ppGpp synthesis, inducing its synthesis or blocking its hydrolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.